复宏汉霖重续与国药控股经销协议 年度上限逐年递增

财中社
Dec 04, 2025

12月3日,复宏汉霖(02696)发布公告,宣布与国药控股的经销框架协议(2025重续)已达成,该协议的初始期限自2023年1月1日起至2025年12月31日止,现已自动续期三年,新的协议有效期自2026年1月1日至2028年12月31日。根据协议,复宏汉霖将继续向国药控股集团销售其产品,预计在2026年、2027年及2028年,每年的交易金额上限分别为38.7亿元、39.01亿元及44.53亿元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10